A critical review of evidence for safe dual antiplatelet therapy use in conjunction with second-generation coronary drug-eluting stent implantation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F12%3A43907131" target="_blank" >RIV/00064173:_____/12:43907131 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

A critical review of evidence for safe dual antiplatelet therapy use in conjunction with second-generation coronary drug-eluting stent implantation

Popis výsledku v původním jazyce

The goal of this rewiev is to describe the evidence for safe dual antiplatelet therapy in conjunction with second-generation drug eluting stents. The new generation of DES using a novel platform (cobalt-chromium thin strut), highly biocompatible polymersand innovative antiproliferative drugs provide better outcomes with respect to in-stent restenosis and subsequent revascularization over DES from the first generation. Currently, development is focused on further improving the efficacy of DES. The long-term safety of newer generations of DES has been established in a number of randomized clinical trials. Second generation DES (especially the everolimus- and zotarolimus-eluting stents) appear to be safe in the long term, at least comparable to BMS. Theuse of DAPT with stents has significantly improved outcomes in patients undergoing PCI with stent implantation. The ESC Guidelines on myocardial revascularization provide practical guidance for current use of DAPT in the clinical setting,

Název v anglickém jazyce

A critical review of evidence for safe dual antiplatelet therapy use in conjunction with second-generation coronary drug-eluting stent implantation

Popis výsledku anglicky

The goal of this rewiev is to describe the evidence for safe dual antiplatelet therapy in conjunction with second-generation drug eluting stents. The new generation of DES using a novel platform (cobalt-chromium thin strut), highly biocompatible polymersand innovative antiproliferative drugs provide better outcomes with respect to in-stent restenosis and subsequent revascularization over DES from the first generation. Currently, development is focused on further improving the efficacy of DES. The long-term safety of newer generations of DES has been established in a number of randomized clinical trials. Second generation DES (especially the everolimus- and zotarolimus-eluting stents) appear to be safe in the long term, at least comparable to BMS. Theuse of DAPT with stents has significantly improved outcomes in patients undergoing PCI with stent implantation. The ESC Guidelines on myocardial revascularization provide practical guidance for current use of DAPT in the clinical setting,

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Confluence: Concepts and Opinions in Interventional Cardiovascular Medicine

ISSN

2041-7594

e-ISSN

—

Svazek periodika

-

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

3-10

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—